Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Frank Bennett

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Molecular Therapy. Nucleic Acids|April 25, 2023
GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cellsMoira A McMahon, Meghdad Rahdar, Swagatam Mukhopadhyay, et al.
Biological Chemistry|February 8, 2011
Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAsJiaxin Hu, Keith T Gagnon, Jing Liu, et al.
Cancer Research|September 20, 2006
HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesisRyoji Fujii, Changjun Zhu, Yunfei Wen, et al.
Cancer Research|October 7, 2010
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapyEran Elyakim, Einat Sitbon, Alexander Faerman, et al.
Nature|August 4, 2012
Targeting nuclear RNA for in vivo correction of myotonic dystrophyThurman M Wheeler, Andrew J Leger, Sanjay K Pandey, et al.
Neurology|February 12, 2016
Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophyClaudia A Chiriboga, Kathryn J Swoboda, Basil T Darras, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Transplantation|February 25, 2005
Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicityWenhau Chen, Robert M Langer, Slawa Janczewska, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 6, 2011
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtinJeffrey B Carroll, Simon C Warby, Amber L Southwell, et al.
Genes & Development|August 17, 2012
TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animalsKentaro Sahashi, Yimin Hua, Karen K Y Ling, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Molecular Therapy. Nucleic Acids|April 25, 2023
GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cellsMoira A McMahon, Meghdad Rahdar, Swagatam Mukhopadhyay, et al.
Biological Chemistry|February 8, 2011
Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAsJiaxin Hu, Keith T Gagnon, Jing Liu, et al.
Cancer Research|September 20, 2006
HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesisRyoji Fujii, Changjun Zhu, Yunfei Wen, et al.
Cancer Research|October 7, 2010
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapyEran Elyakim, Einat Sitbon, Alexander Faerman, et al.
Nature|August 4, 2012
Targeting nuclear RNA for in vivo correction of myotonic dystrophyThurman M Wheeler, Andrew J Leger, Sanjay K Pandey, et al.
Neurology|February 12, 2016
Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophyClaudia A Chiriboga, Kathryn J Swoboda, Basil T Darras, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Transplantation|February 25, 2005
Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicityWenhau Chen, Robert M Langer, Slawa Janczewska, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 6, 2011
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtinJeffrey B Carroll, Simon C Warby, Amber L Southwell, et al.
Genes & Development|August 17, 2012
TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animalsKentaro Sahashi, Yimin Hua, Karen K Y Ling, et al.
Pageof 17